FGFR3 and neoplasm: Notably, the anti‐FGFR3 antibody alone exhibited negligible inhibition of tumor growth, confirming that the cytotoxic payload A2 is the core effector molecule responsible for LZU‐WZLYCS01's antitumor activity.